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Objectives: Among the bone-targeted agents (BTAs) currently approved for the pre-
vention of skeletal-related events (SREs), several characteristics may be considered 
by physicians when making treatment decisions. This study evaluated Canadian 
physicians’ treatment preferences for BTAs used to prevent SREs in patients with 
bone metastases from solid tumors. MethOds: Physicians treating patients with 
bone metastases from solid tumors completed a web-enabled discrete-choice 
experiment survey consisting of 10 choices between pairs of hypothetical medica-
tion profiles for patient with either breast or prostate cancer. Each hypothetical 
medication profile included five attributes within a pre-defined range (primarily 
based on prescribing information): months until first SRE (10, 18 and 28 months); 
months until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis 
of the jaw (ONJ; 0%, 1% and 5%); annual risk of renal impairment (0%, 4% and 10%); 
and mode of administration (oral tablet, subcutaneous injection, 15-minute infu-
sion and 120-minute infusion). Choice questions were based on an experimental 
design with known statistical properties. The survey was pretested with 8 physicians 
using open-ended interviews. A main-effects random parameters logit model was 
used to analyze the data. Results: A total of 200 Canadian physicians completed 
the survey. Over the attribute levels included, months until first SRE, the risk of 
renal impairment, and months until worsening of pain were the most important 
attributes. For those attributes, better levels (outcomes) were significantly preferred 
to worse levels (P < 0.05). For mode of administration, subcutaneous injection was 
preferred over infusion regardless of duration (P < 0.05). cOnclusiOns: When 
making treatment decisions regarding choice of BTA for patients with bone metas-
tases, delaying the onset of SREs and managing the risk of renal impairment are the 
primary considerations for Canadian physicians. Also, respondents had well-defined 
preferences for subcutaneous injections over infusion every 4 weeks.
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Objectives: It is unclear whether the conceptual coverages of the instruments 
available to evaluate the health-related quality of life (HRQoL) of multiple myeloma 
(MM) patients are adequate in the relapsed or refractory (R/R) setting, with respect 
to the FDA’s patient-reported outcome (PRO) guidance. To address this uncertainty, 
we conducted qualitative interviews with R/R MM patients and compared the results 
to the conceptual frameworks of three existing instruments. MethOds: Two con-
secutive sets (n= 15 and n= 8) of qualitative concept elicitation (CE) interviews were 
conducted with R/R MM patients in the U.S. The concepts reported were compared 
with the conceptual frameworks of the EORTC QLQ-C30 and QLQ-MY20, FACT-MM, 
and MDASI-MM. In addition, a conceptual model was devised based on the results of 
these interviews, and an analysis of the relative timing (with respect to treatment/
disease course) of the reported symptoms and impacts was conducted. Results: 
A total of 23 R/R MM patients (age range= 50 to 89 years; mean age= 66.7±10.1 years; 
male= 56.5%) participated in the CE interviews. A total of 37 symptom concepts 
and 55 HRQoL impacts were reported. Of the six symptom concepts reported by 
> 2 patients, five (83.3%) were covered by the QLQ-C30 and MY-20, three (50.0%) by 
the FACT-MM, and three (50.0%) by the MDASI-MM. Of the 23 impacts reported by 
> 2 patients, 14 (60.9%) were covered by the QLQ-C30 and MY-20, 9 (39.1%) by the 
FACT-MM, and 7 (30.4%) by the MDASI-MM. Analysis of the timing of symptom/
impact reporting revealed that the majority of concepts noted by > 2 MM patients 
were present both pre- and post-relapse. cOnclusiOns: These findings indicate 
that the EORTC QLQ-C30 and QLQ-MY20 instruments are appropriate for captur-
ing the symptom and impact domains most often reported by R/R MM patients, 
although room may remain for improvement in assessing functional impacts at 
the conceptual level in this population.
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Objectives: To perform a qualitative patient interview study using an internet-
based digital patient platform for recruitment and telephone and webcam for 
interviews. MethOds: To design the qualitative study we followed the steps out-
lined in the ISPOR PRO Good Research Practices Task Force Report: Part 1 (Patrick 
et al, 2011). Briefly, a qualitative interview guide was developed and approved by 
IRB. Participants were recruited, consented, enrolled, and interviewed online. Each 
interview was audio recorded and transcribed. Analysis of the qualitative data was 
performed by experienced market researchers. Results: Screening, demographic, 
and medical information was gathered directly from patients online, via the inter-
net, with no interaction from the patient’s physician(s) or site. Existing members 
of MediGuard, an online free medication monitoring service, were sent an email 
invitation to participate in the study. Members who choose to click on the link were 
directed to a website where they accessed information regarding the study, provided 
consent to participate, self-screened for eligibility, and reported baseline character-
istics. Consented participants were contacted via phone to schedule a time to par-
ticipate in an individual interview via telephone or webcam. Interviews were audio 
recorded, and lasted 60-75 minutes. 17 patients were interviewed. cOnclusiOns: 
Recruiting and interviewing patients via the internet and phone is a feasible, faster, 
and potentially lower cost alternative to face to face interviews. Some benefits of 
direct to patient research include potential to reduce patient travel burden to a study 
pleted the EQ-5D-5L. Inclusion criteria were current chronic phase of CML, visits after 
June 2012, and age ≥ 18 years at diagnosis. The analysis included descriptive statistics 
of the sample population and derivation of a utility value for each patient. Kruskal 
Wallis test was conducted to compare the utility values for non-parametric data, and 
t test was conducted for parametric data. A utility value of 0 implies death, while a 
value of 1 implies full health. Results: Out of the 81 questionnaires that were mailed 
33 (40.7%) were returned. Three returned questionnaires were excluded due to failure 
to complete the instrument, and one patient passed away. Of the 29 patients in the 
final sample, there are 15 males, the mean age was 54.3±15.0 years, the mean utility 
was 0.79±0.15, and the mean duration of CML was 5.1±3.6 years. For current CML treat-
ments, 3 patients had undergone stem cell transplantation (SCT), 25 patients were 
receiving tyrosine kinase inhibitors (TKIs), and one patient discontinued medication 
due to adverse events. Overall, the mean utility difference between SCT and TKIs was 
not statistically significant (0.72± 0.15 vs. 0.80 ± 0.15, p= 0.35). Among TKIs, Imatinib 
had the highest utility scores (0.88±0.14, n= 10), followed by ponatinib (0.83±0.15, n= 3), 
nilotinib (0.81±0.04, n= 3), dasatinib (0.72±0.12, n= 8), and bosutinib (0.48, n= 1). There 
was no statistical difference in utilities in patients who received one line of treat-
ment (0.83±0.15, n= 13) vs. multiple lines (0.76±0.15, n= 12, p= 0.22). cOnclusiOns: 
Although the study population was small, our results indicate that current US CML 
patients have good QoL scores. A larger sample size is needed for further research.
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Objectives: Carcinoid tumors are a type of neuroendocrine tumor (NET), most 
often occurring in the gastrointestinal tract. These tumours are rare and difficult 
to identify, since symptoms are often associated with other conditions. Once cor-
rectly diagnosed, many symptomatic patients are treated with Sandostatin LAR. This 
study sought to identify the typical NET patient journey, from onset of symptoms to 
diagnosis and treatment. MethOds: 75 NET patients that are currently treated with 
Sandostatin LAR were interviewed by telephone using a 30-minute structured ques-
tionnaire comprised of a mix of closed-ended and open-ended questions. Results: 
More than three quarters (76%, n= 57) of patients presented with symptoms prior 
to NET diagnosis. 74% of these symptomatic patients (n= 42) were first seen by a 
general practitioner / family doctor. However NET was recognised within 1 year in 
only 51% of cases (n= 29), while in the remaining 49% of cases it took more than a 
year to correctly diagnose NET. Out of all asymptotic patients (n= 18), in 39% cases 
(7/18*100%; n= 7) the tumors were found incidentally while the patient was under-
going treatment for another condition, while in 33% cases (6/18*100%; n= 6) NET 
condition was discovered due to abnormal test results. Two-fifths (43%, n= 32) of 
respondents were misdiagnosed prior to receiving NET diagnosis, with 53% (n= 17) 
of misdiagnosed cases persisting for more than 1 year. Overall, 83% of the sample 
saw 2 or more physicians before NET was diagnosed. cOnclusiOns: The results of 
this research indicate that Canadian patients can experience significant delays in 
the correct diagnosis and appropriate treatment of NET. This is attributable in part 
to the nonspecific nature of the signs and symptoms of NET, but also due to a lack 
of awareness of NET among frontline physicians and the general public.
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Objectives: To examine relative preferences for symptoms, treatment-related side-
effects and progression-free survival (PFS) in women with ovarian cancer using 
a discrete choice experiment (DCE). MethOds: A pilot study was conducted of 
women with advanced or recurrent ovarian cancer. In the DCE, participants were 
asked to choose between two treatment scenarios, modeled on characteristics of 
standard intravenous (IV) and intraperitoneal/intravenous (IP/IV) treatments for 
newly diagnosed ovarian cancer. Each scenario included 7 attributes with 2-3 levels 
each: mode of administration (IV versus IP/IV); visit frequency (one per week, two 
per 3 weeks, one per 3 weeks); treatment-related abdominal symptoms, neuropathy, 
fatigue, nausea, and vomiting; and PFS (15, 18, 21 and 24 months). We used a bal-
anced overlap design with 10 versions of the survey. Each participant evaluated 12 
random choice and one fixed-choice scenario. Mixed logit regression modeled par-
ticipant’s choices as a function of attribute levels. Results: 95 women completed 
the survey. Mean age was 57 and 81% were Caucasian. Half (47%) had experienced 
disease recurrence and 49% were currently receiving chemotherapy. Compared to 
scenarios with 15 months of PFS, the relative odds that a participant would choose 
a scenario with 18, 21 and 24 months of PFS were 1.5 (p= 0.01), 3.4 (p< 0.001) and 7.5 
(p< 0.001), respectively. Assuming a linear relationship with PFS, on average, patients 
were willing to tradeoff 6.7 months of PFS for an improvement from severe to mild 
nausea and vomiting during treatment, 5.0 months of PFS for an improvement from 
severe to mild neuropathy, and 3.7 months of PFS for an improvement from severe to 
moderate abdominal symptoms. cOnclusiOns: Progression-free survival time is 
the most important factor in determining preferences for chemotherapy regimens. 
However, women with ovarian cancer were willing to give up significant amounts 
of PFS time for marked reductions in the severity of treatment-related side effects.
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